Clinical and economic review report: Vedolizumab (ENTYVIO SC) Takeda Canada Inc. indication: Crohn disease
The objective of the current review was to perform a review of the beneficial and harmful effects of vedolizumab subcutaneous in adult patients with moderately to severely active Crohn disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a tum...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, April 2021
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of the current review was to perform a review of the beneficial and harmful effects of vedolizumab subcutaneous in adult patients with moderately to severely active Crohn disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a tumour necrosis factor alpha antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids |
|---|---|
| Physical Description: | 1 PDF file (92 pages) illustrations |